SCHEMBL1904697

SCHEMBL1904697

COc1cc2c(NC(C)c3ccccn3)c(C(N)=O)cnc2cc1-c1c(C)noc1C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 12/20 0.69
CYP2C9 P11712 12/20 0.69
BRD4 O60885 12/20 0.66
BRD2 P25440 5/20 0.66
BRD3 Q15059 5/20 0.66
CYP2C19 P33261 2/20 0.65
PDE4B Q07343 2/20 0.65
CACNA1A O00555 1/20 0.57
CHRNA1 P02708 1/20 0.57
CYP2D6 P10635 1/20 0.57
CCL2 P13500 1/20 0.57
KCNA5 P22460 1/20 0.57
TACR1 P25103 1/20 0.57
MAOB P27338 1/20 0.57
AVPR1A P37288 1/20 0.57
KCNH2 Q12809 1/20 0.57
SCN5A Q14524 1/20 0.57
BRDT Q58F21 1/20 0.57
CREBBP Q92793 1/20 0.57
KCNH3 Q9ULD8 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1902577 1.00 CYP3A4 (0.69) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL13731747 0.90 CYP3A4 (0.72) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL12096364 0.88 BRD4 (0.62) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL1907655 0.88 BRD4 (0.62) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL1907697 0.84 BRD4 (0.57) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL1907500 0.83 CYP3A4 (0.68) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL14756281 0.82 CYP3A4 (0.75) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL1905638 0.82 BRD4 (0.64) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL25197524 0.81 BRD4 (0.66) CYP3A4CYP2C9BRD4BRD2BRD3
SCHEMBL18904314 0.80 CYP3A4 (0.70) CYP3A4CYP2C9BRD4BRD2BRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240050576-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2024-02-15 US disclosed
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE Design Therapeutics, Inc. 2023-05-18 US disclosed
EP-2496576-B1 IMIDAZO[4,5-C]QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-12-18 EP disclosed
US-8557984-B2 Imidazo [4, 5-C] quinoline derivatives as bromodomain inhibitors GLAXOSMITHKLINE LLC (US) 2013-10-15 US disclosed
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors GLAXOSMITHKLINE LLC 2012-09-13 US disclosed
EP-2496576-A1 IMIDAZO [4, 5-C]QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS GlaxoSmithKline LLC (US) 2012-09-12 EP disclosed
WO-2011054846-A1 IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS GLAXOSMITHKLINE LLC (US) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149550-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE DMPK, DTYMK, MYCBP CYP3A4 4885/4885CYP2C9 4879/4885BRD4 928/4885
US-20120232074-A1 Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors BRD4, BRD3, BRPF3 CYP3A4 1579/4885CYP2C9 3411/4885BRD4 1/4885
US-20240050576-A1 METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE ZFX, GRN, F13B CYP3A4 4868/4885CYP2C9 4852/4885BRD4 930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.